ISPOR - HTA93 Time to Reimbursement of Novel Anticancer Drugs in Ireland Compared to Six European Countries and the UK

Full Text

HTA93 Time to Reimbursement of Novel Anticancer Drugs in Ireland Compared to Six European Countries and the UK

Abstract

Authors

S. Redmond N. O'Flatharta

Back to Volume 26, Supplemental Issue 12S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now